Biologic therapy for psoriasis is associated with the development of metabolic dysfunction-associated steatotic liver disease (MASLD). A study on the association of cardiometabolic conditions with psoriasis treatment

Gwyneth Armijo-Borjon, Alessandra Irais Miranda-Aguirre, Arnulfo Garza-Silva, Iván Francisco Fernández-Chau, Miguel Ángel Sanz-Sánchez, Arnulfo González-Cantú, Maria Elena Romero-Ibarguengoitia*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Psoriasis requires a comprehensive assessment of concomitant diseases to make better therapeutic decisions. This study examined the differences in the onset and progression of associated cardiometabolic comorbidities in psoriasis patients based on their treatments. Methods: A retrospective longitudinal study was conducted on patients aged over 13 years with psoriasis seen at a Northern Mexican Hospital between 2012 and 2023. Patients were categorized into three groups according on the type of treatment received: topical, systemic, and biologic. A logistic regression analysis was performed to identify predictors of comorbidity development. Results: 197 patients were included; 52.8% were women, with a mean (SD) age of 54.45 (16.91) years, divided into topical [n = 90 (45.7%)], systemic [n = 57 (29.1%)], and biologic [n = 50 (25.5%)] groups, metabolic dysfunction-associated steatotic liver disease (MASLD) was significantly more prevalent in the biologic group [22 (44%)], p < 0.001. The logistic regression showed that type 2 diabetes mellitus, biological treatments (OR = 5.798, p = 0.001), and body mass index (OR = 1.144, p = 0.002), predicted the development of MASLD with a Nagelkerke’s R2 of 0.400. Conclusions: Psoriasis patients using biological therapies have a greater predisposition to MASLD. These patients should receive a comprehensive approach to identify metabolic conditions, and screening tests for MASLD are recommended.

Original languageEnglish
Article number195
JournalArchives of Dermatological Research
Volume317
Issue number1
DOIs
Publication statusPublished - Dec 2025
Externally publishedYes

Bibliographical note

Publisher Copyright:
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024.

All Science Journal Classification (ASJC) codes

  • Dermatology

Fingerprint

Dive into the research topics of 'Biologic therapy for psoriasis is associated with the development of metabolic dysfunction-associated steatotic liver disease (MASLD). A study on the association of cardiometabolic conditions with psoriasis treatment'. Together they form a unique fingerprint.

Cite this